Iritec 40mg/2ml & 100mg/5ml injection Vial
Irinotecan is a semisynthetic derivative of Camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of type I DNA topoisomerase. It is metabolized by carboxylesterases in most tissues, thus yielding SN-38, which was found to be more active than Irinotecan on purified type I topoisomerase and more cytotoxic than Irinotecan against several human and murine tumour lines.
Share Now
Additional Information
| Name | Iritec |
| Description | Irinotecan is a semisynthetic derivative of Camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of type I DNA topoisomerase. It is metabolized by carboxylesterases in most tissues, thus yielding SN-38, which was found to be more active than Irinotecan on purified type I topoisomerase and more cytotoxic than Irinotecan against several human and murine tumour lines. Inhibition of type I DNA topoisomerase by Irinotecan or SN-38 induces lesions in the single-stranded DNA, and these lesions block DNA replication fork and are responsible for the cytotoxicity. This cytotoxic effect was found to be time dependent and S-phase specific. |
| Active Ingredient | Irinotecan |
| Indication | Irinotecan in combination therapy is indicated for the following cancer types:
|
| Strengths | 40mg/2ml & 100mg/5ml |
| Business Partner | Vianex S.A |
| Origin | Greece |
Related Products
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.
